CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 4,293 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

CRISPR Therapeutics Price Performance

CRSP traded up $0.22 on Tuesday, hitting $48.05. The company had a trading volume of 867,601 shares, compared to its average volume of 1,461,021. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $91.10. The stock has a fifty day simple moving average of $47.13 and a 200-day simple moving average of $53.77. The firm has a market capitalization of $4.08 billion, a P/E ratio of -17.43 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. During the same period in the previous year, the business earned ($0.98) EPS. CRISPR Therapeutics’s revenue for the quarter was down 99.3% compared to the same quarter last year. Equities research analysts expect that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Global Trust Asset Management LLC increased its stake in shares of CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC increased its stake in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares in the last quarter. Riggs Asset Managment Co. Inc. increased its stake in shares of CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics during the second quarter valued at approximately $35,000. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CRSP shares. Barclays reduced their target price on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Friday, August 16th. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Chardan Capital reduced their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $75.19.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.